Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch

Diabetes Technology & Therapeutics
Michael P StoneFrancine R Kaufman

Abstract

Real-world data from the first 3141 patients who completed 3 months of SmartGuard™ Auto Mode-enabled MiniMed™ 670G system use during the MiniMed 670G System Commercial Launch are reported. CareLink™ system data uploaded by real-world patients in the Commercial Launch from March 17, 2017 to December 31, 2017 were deidentified and analyzed. Comparisons of overall and night (10:00 PM-07:00 AM) time spent below, within, and above target glucose range (TIR) (70-180 mg/dL) between the baseline Manual Mode and closed-loop Auto Mode periods were made. These were evaluated alongside data from the 124 patients (aged 14-75 years) who completed the 3-month MiniMed 670G system pivotal trial (NCT 2463097), from June 2, 2015 to March 7, 2016. Real-world patients used Auto Mode a median 80.8% of the time (19 h and 24 min of the day). The overall mean of time spent in TIR was 66.0% during baseline Manual Mode versus 73.3% during Auto Mode (P < 0.001); the mean percentage of sensor glucose values <70 mg/dL was 2.7% versus 2.1% (P < 0.001); and that >180 mg/dL was 31.4% versus 24.6% (P < 0.001). The nighttime and early morning (03:00 AM-06:00 AM) TIR during Auto Mode was greater than that during baseline Manual Mode (nighttime: 77.2% vs. 67.4% [P...Continue Reading

References

Sep 2, 2016·European Respiratory Review : an Official Journal of the European Respiratory Society·Rosanna TarriconePatrizio Armeni
Sep 16, 2016·JAMA : the Journal of the American Medical Association·Richard M BergenstalFrancine R Kaufman
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
May 26, 2017·Diabetes Technology & Therapeutics·Lorena Alarcon-Casas Wright, Irl B Hirsch

❮ Previous
Next ❯

Citations

Aug 29, 2018·Journal of Diabetes·Robert A Vigersky
Oct 15, 2019·Journal of Diabetes Science and Technology·Pau HerreroPantelis Georgiou
Nov 9, 2019·Diabetologia·Andrew Advani
May 23, 2019·Journal of Diabetes Science and Technology·Jitendra GuptaThomas Sparre
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
May 19, 2020·Diabetic Medicine : a Journal of the British Diabetic Association·L DowlingP Choudhary
Jun 7, 2019·Diabetes Technology & Therapeutics·Mary L JohnsonRichard M Bergenstal
Aug 24, 2019·Diabetes & Metabolism Journal·Giacomo CapponAndrea Facchinetti
Sep 25, 2019·Diabetes Care·Rayhan A LalDarrell M Wilson
Aug 28, 2020·Diabetes Technology & Therapeutics·Jordan E PinskerSteph Habif
Aug 28, 2020·The New England Journal of Medicine·Marc D BretonUNKNOWN iDCL Trial Research Group
Jan 8, 2021·Current Nutrition Reports·Melissa J Schoelwer, Mark D DeBoer
Dec 11, 2020·Diabetes Care·UNKNOWN American Diabetes Association
Mar 24, 2021·Reviews in Endocrine & Metabolic Disorders·Federico Boscari, Angelo Avogaro
Mar 25, 2021·Journal of Medical Internet Research·Claudia EberleMaxine Löhnert
Sep 19, 2020·The Lancet. Diabetes & Endocrinology·Medha N MunshiAlan J Sinclair
Nov 14, 2020·Diabetes Technology & Therapeutics·Revital NimriMoshe Phillip
Mar 31, 2021·Diabetes Technology & Therapeutics·Pilar Isabel Beato-VíboraFrancisco Javier Arroyo-Díez
May 8, 2021·Canadian Journal of Diabetes·Linda R WangKori A LaDonna
May 18, 2021·Diabetes, Obesity & Metabolism·Roshell JeyaventhanSufyan Hussain
Jun 15, 2021·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Laura M NallyMichelle Van Name
Sep 16, 2021·Diabetes Technology & Therapeutics·Anastasia Albanese-O'NeillRagnar Hanas
Sep 16, 2021·Diabetes Technology & Therapeutics·Stephanie N DuBoseUNKNOWN HYCLO Study Group
Oct 19, 2021·Diabetes, Obesity & Metabolism·Torben BiesterKlemen Dovc
Nov 14, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Christine KnollKatarina Braune

❮ Previous
Next ❯

Software Mentioned

CareLink
SmartGuard
Auto Mode

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.